Bristol Myers Squibb (CELG-RI) Income from Non-Controlling Interests (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Income from Non-Controlling Interests of $1.0 million for Q1 2026, down 83.33% YoY from $6.0 million in Q1 2025, and up 200.0% sequentially from -$1.0 million in Q4 2025.
Bristol Myers Squibb (CELG-RI) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Bristol Myers Squibb has disclosed Income from Non-Controlling Interests across 18 years of filings, most recently posting $1.0 million for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 83.33% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at -$4.0 million (down 122.22% YoY), while the FY2025 annual figure was $2.0 million, down 86.67% from the prior year.
- Income from Non-Controlling Interests climbed to $1.0 million in Q1 2026, from -$1.0 million in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for CELG-RI reached as high as $8.0 million in Q2 2022 and fell as low as -$6.0 million in Q3 2025.
- The 5-year median for Income from Non-Controlling Interests is $4.0 million (2023), against an average of $3.1 million.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests jumped 200.0% — and 2025, when it tumbled 250.0%.
- A 5-year view of Income from Non-Controlling Interests shows it stood at $3.0 million in 2022, then jumped by 100.0% to $6.0 million in 2023, then sank by 33.33% to $4.0 million in 2024, then plunged by 125.0% to -$1.0 million in 2025, then jumped by 200.0% to $1.0 million in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $1.0 million, -$1.0 million, and -$6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Sep 30, 2025 | -6.00 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | 4.00 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Sep 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 3.00 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Sep 30, 2021 | 6.00 Mn |
| Jun 30, 2021 | 6.00 Mn |
| Mar 31, 2021 | 8.00 Mn |
| Sep 30, 2020 | 6.00 Mn |